402 related articles for article (PubMed ID: 33218938)
1. AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Zheng L; Li S; Zheng X; Guo R; Qu W
Int Immunopharmacol; 2021 Jan; 90():107185. PubMed ID: 33218938
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
3. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
4. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.
Xue G; Lin X; Wu JF; Pei D; Wang DM; Zhang J; Zhang WJ
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32766727
[TBL] [Abstract][Full Text] [Related]
5. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.
Zheng M; Liu J; Bian T; Liu L; Sun H; Zhou H; Zhao C; Yang Z; Shi J; Liu Y
Int Immunopharmacol; 2021 Jan; 90():107134. PubMed ID: 33168407
[TBL] [Abstract][Full Text] [Related]
6. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
[TBL] [Abstract][Full Text] [Related]
9. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
12. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
13. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics analysis of the clinical value and potential mechanisms of AHNAK2 in papillary thyroid carcinoma.
Xie Z; Lun Y; Li X; He Y; Wu S; Wang S; Sun J; He Y; Zhang J
Aging (Albany NY); 2020 Sep; 12(18):18163-18180. PubMed ID: 32966238
[TBL] [Abstract][Full Text] [Related]
15. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
16. CXCL10 is a potential biomarker and associated with immune infiltration in human papillary thyroid cancer.
Qin XJ; Lin X; Xue G; Fan HL; Wang HY; Wu JF; Pei D
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33345267
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of PINX1 expression in papillary thyroid carcinoma.
Kang J; Han K; Kim HJ; Park JH; Kong JS; Park S; Myung JK
Hum Pathol; 2018 Nov; 81():176-183. PubMed ID: 30026037
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
19. VDR is a potential prognostic biomarker and positively correlated with immune infiltration: a comprehensive pan-cancer analysis with experimental verification.
Xia X; Xu F; Dai D; Xiong A; Sun R; Ling Y; Qiu L; Wang R; Ding Y; Lin M; Li H; Xie Z
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38639057
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA signature predicts survival in papillary thyroid carcinoma.
Chengfeng X; Gengming C; Junjia Z; Yunxia L
J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
